---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: American hospital formulary service (AHFS), or other drug classification"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: American hospital formulary service (AHFS), or other drug classification. Topics: AHFS patient medication information class of crizotinib, Crizotinib established class in the prescribing information, WHO Anatomical Therapeutic Chemical classification of crizotinib, and NCI Drug Dictionary classification of darovasertib. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/american-hospital-formulary-service-ahfs-or-other-drug-classification"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: American hospital formulary service (AHFS), or other drug classification

<a id="heading-2.1.2.4"></a>

## 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

### AHFS patient medication information class of crizotinib

> “Crizotinib is in a class of medications called kinase inhibitors.”
> “AHFS® Patient Medication Information™. © Copyright, 2026.”

Source: [MedlinePlus crizotinib drug information (2022)](https://medlineplus.gov/druginfo/meds/a612018.html)

<a id="topic-2.1.2.4-2"></a>

### Crizotinib established class in the prescribing information

> “Crizotinib is a kinase inhibitor.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.4-3"></a>

### WHO Anatomical Therapeutic Chemical classification of crizotinib

| ATC code | Name | Defined daily dose | Unit | Route |
| --- | --- | --- | --- | --- |
| “L01ED01” | “crizotinib” | “0.5” | “g” | “O” |

Source: [WHO Collaborating Centre ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L01ED01)

> “L01ED Anaplastic lymphoma kinase (ALK) inhibitors”
> “Substances which are multi-targeted, but where ALK is considered the main target, are classified in this group.”

Source: [WHO Collaborating Centre ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L01ED01)

<a id="topic-2.1.2.4-4"></a>

### NCI Drug Dictionary classification of darovasertib

> “An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities.”

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/darovasertib)

<a id="topic-2.1.2.4-5"></a>

### AHFS and ATC classification of darovasertib

No evidence found.

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
